{"organizations": [], "uuid": "4f092f6837808e2770a95227010a7aa2f70f9006", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets", "section_title": "Markets &amp; Finance News | Reuters.com", "url": "https://www.reuters.com/article/brief-biohaven-says-expects-topline-resu/brief-biohaven-says-expects-topline-results-from-phase-3-trial-with-rimegepant-zydis-odt-in-q4-idUSASB0C8WZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.531, "site_type": "news", "published": "2018-03-06T16:07:00.000+02:00", "replies_count": 0, "uuid": "4f092f6837808e2770a95227010a7aa2f70f9006"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biohaven-says-expects-topline-resu/brief-biohaven-says-expects-topline-results-from-phase-3-trial-with-rimegepant-zydis-odt-in-q4-idUSASB0C8WZ", "ord_in_thread": 0, "title": "BRIEF-Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - biohaven pharmaceutical holding company ltd", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:\n* BIOHAVEN ENROLLS FIRST PATIENT IN PHASE 3 CLINICAL TRIAL TO EVALUATE RIMEGEPANT ZYDIS® ODT IN THE ACUTE TREATMENT OF MIGRAINE\n* BIOHAVEN - CONTINUES TO EXPECT TOPLINE RESULTS FROM TWO PHASE 3 TRIALS EXAMINING EFFICACY OF RIMEGEPANT 75 MG ORAL TABLET VERSUS PLACEBO BY END OF Q1 2018​\n* BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD SAYS ‍EXPECTS TOPLINE RESULTS FROM PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q4 OF 2018​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T16:07:00.000+02:00", "crawled": "2018-03-06T10:57:30.010+02:00", "highlightTitle": ""}